Biotech Values

[dav1234]

Johnson & Johnson (JNJ) plans to seek FDA approval in Q2 to use its Xarelto treatment for preventing lung clots after a large-scale Phase III study showed that the drug is as effective as and safer than standard treatments, which include Warfarin. Lung clots affect 600K Americans a year and kill up to 100K